. home.aspx



Promising early data for MSDs investigational HIV drug

July 24, 2019 / Anna Smith

MSD has announced results from a Phase I study evaluating the pharmacokinetics and safety of a prototype subdermal drug-eluting implant for islatravir, an antiretroviral therapeutic for the prevention and treatment of HIV. The investigational drug is a nucleoside reverse transcriptase translocation inhibitor (NRTTI), and MSD is currently conducting a broad development program to evaluate the potential of the therapy for the treatment and prevention of HIV-1 infection. The Phase I double-blind, placebo-controlled study found that the implant containing 62mg of the drug was estimated to deliver levels well above the threshold at 12 months, providing early evidence for its potential as a once-yearly option for PrEP. The company is also exploring several potential options for PrEP, including a drug-eluting implant and a once-monthly oral formulation. The company is “encouraged by the results of this proof of concept study exploring the potential of delivering meaningful doses of isla...